The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.

Patients sub-optimally controlled on basal insulin (with/without other antihyperglycemic agents (AHAs)) will be randomized 1:1 to either Finesse or pen to initiate bolus insulin dosing and followed for a 44-week intervention period. Patients will have both basal and bolus doses of insulin adjusted throughout the trial, as is clinically indicated, based on an easy to follow insulin dosing algorithm. After the final endpoint evaluation at week 44, patients will crossover to the alternate bolus insulin delivery device for 4 weeks and complete a patient preference survey at week 48.

Change in percent of glucose values of Continuous Glucose Monitoring (CGM) measurements within targeted range of 71 and 180 mg/dl (4.0 and 10.0 mmol/l) from baseline to week 24 (in a subset of patients)

Change in A1C From Baseline to Week 44 [ Time Frame: 44 weeks ]

Change in A1C from baseline to the completion of 44 weeks of basal and bolus insulin therapy

Number of Patients With A1C ≤7.0% at Week 44 [ Time Frame: 44 weeks ]

Number of patients with A1C ≤7.0% after 44 weeks of basal and bolus insulin therapy

Change in A1C From Week 24 to Week 44 [ Time Frame: 44 weeks ]

Change in A1C from week 24 to week 44 after basal and bolus insulin therapy

Number of Participants With Severe Hypoglycemic Event [ Time Frame: 44 weeks ]

An event requiring the assistance of another person to actively administer carbohydrate (including IV dextrose), glucagon, or other resuscitative actions. Neurological recovery attributable to the restoration of plasma glucose to normal is considered sufficient evidence that the event was induced by a low plasma glucose concentration.

Change in treatment satisfaction with insulin delivery system from baseline to week 24 was assessed by self-report on the validated Insulin Delivery System Rating Questionnaire. Scale is 0-100. Higher score is better.

Change in Quality of Life From Baseline to Week 24 [ Time Frame: 24 weeks ]

Change in Diabetes-Specific Quality of Life (QOL), baseline to week 24. was assessed by self-report on the validated Diabetes Specific Quality of Life Survey. Scale is 0-100. Higher score is better.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:

22 Years to 75 Years (Adult, Older Adult)

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

No

Criteria

Inclusion Criteria:

Clinical diagnosis of T2DM

Treated with basal insulin for ≥ 6 months, with current dose stable for ≥ 6 weeks of ≥ 0.3 U/kg/day, with or without anti-hyperglycemic agents and in whom the Investigator feels advancement from basal to basal and bolus therapy is needed for the patient

A1C 7.5-11.0% by central lab value at screening visit

Already perform self-monitoring of blood glucose (SMBG) and willing to test blood glucose (BG) over the course of the study

Body Mass Index of ≤ 40 kg/m2

Exclusion Criteria:

Currently on or has been treated in the past year with insulin regimens that include bolus insulins except the need for insulins in the settings of acute illness or hospitalization

History of type 1 diabetes mellitus (T1DM), or diabetic ketoacidosis (DKA), or secondary forms of diabetes such as cystic fibrosis

Known hypersensitivity or allergy to insulin-glargine or its excipients or any other insulins

Two or more severe hypoglycemic episodes within the prior year

Hypoglycemia unawareness defined by history

History of proliferative diabetic retinopathy

Is currently unstable and/or has moderate-to-severe medical illness in the Investigator's judgment